ABBV vs LLY: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Eli Lilly and Company · Healthcare
$1,183.72
+2.1% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
LLY has more upside to fair value
(+2.1%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
LLY |
| Current Price |
$261.70 |
$1,183.72 |
| Fair Value Estimate |
$259.04 |
$1,208.00 |
| Upside to Fair Value |
-1.0%
|
+2.1%
|
| Market Cap |
$462.4B |
$1,114.8B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
26.8x
|
| Price / Sales |
7.2x
|
14.0x
|
| Price / FCF |
23.6x
|
52.7x
|
| Revenue Growth YoY |
+10.2%
|
+47.7%
|
| Gross Margin |
71.5%
|
83.4%
|
| Operating Margin |
29.3%
|
49.7%
|
| Return on Equity |
-136.5%
|
92.6%
|
| Dividend Yield |
2.61% |
0.57% |
| FCF Yield |
4.25%
|
1.9%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Eli Lilly is a global pharmaceutical company whose incretin franchise, led by Mounjaro and Zepbound, has become the dominant growth engine in diabetes and obesity care. The business quality is high: TTM gross margin is 83.4%, TTM operating margin is 49.7%, TTM net margin is 33.5%, and ROE is 92.6%, while revenue grew 47.7% and earnings grew 25.3% in the most recent quarter on a year-over-year bas…
Accumulation Zones
| Metric |
ABBV |
LLY |
| Zone Low |
$194.28 |
$906.00 |
| Zone High |
$220.18 |
$1,026.80 |
| In Buy Zone? |
No
|
No
|